GLPwatch
Papers (12034)
Page 157 of 201, ranked by citation count.
- Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.
- In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.
- Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.
- Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.
- The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
- Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk.
- Med14 phosphorylation shapes genomic response to GLP-1 agonists.
- Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials.
- [An orally administered glucagon-like peptide 1 (GLP1) analogue: A landmark in the treatment of type 2 diabetes].
- Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment.
- Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
- Is there a role for the incretin system in blood pressure regulation?
- Tirzepatide, Mortality, Cardiovascular, and Renal Outcomes in Sleep Apnea: Evidence From Real World Data.
- Endoscopic and Open Carpal Tunnel Release in Patients With Type II Diabetes Mellitus: Influence of Preoperative Semaglutide Use on Postoperative Outcomes.
- GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.
- Coverage is the Key to Realizing the Promise of Semaglutide.
- Proteomic Profiling of GLP-1-Mediated Cardioprotection in a Large Animal Model of Chronic Coronary Artery Disease.
- Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.
- [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
- In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Pattern of semaglutide prescription in a real-world Canadian patient cohort.
- Tirzepatide improves cardiorenal health in obese individuals with HFpEF.
- [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
- Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
- Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).
- Semaglutide Adherence and Cardiovascular Diseases in Patients With Type 2 Diabetes: Evidence From Real-World Data in Japan.
- Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy.
- Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
- Unremitting Nausea Due to Lurasidone After Semaglutide Initiation.
- Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report.
- A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models.
- JNK3 regulates β cell responses to incretins in human islets and mouse models.
- Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation.
- Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs.
- Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.
- Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.
- Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?
- Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).
- Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes.
- Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.
- Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.
- Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.
- Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial.
- Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning.
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
- Clinical experience with liraglutide.
- Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.
- Evaluation of the Short-Term Effect of Tirzepatide on Liver Fibrosis Biomarkers Stratified by the Fibrosis-3 Index (FIB-3) in Patients With Type 2 Diabetes Mellitus.
- Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.
- Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study.
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide.
- Understanding Weight Regain After Tirzepatide Withdrawal.
- Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.
- Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.
- Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.
- A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C.